Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose nivolumab in TMB-high advanced solid tumors
2026-525445-73-00Phase 2Authorised
- Sponsor
- UZ Brussel
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Nonhematologic neoplasms, sponsored by UZ Brussel. Primary endpoint: Overall response rate. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2026-525445-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525445-73-00.